Acadia Pharmaceuticals (ACAD) Asset Utilization Ratio (2011 - 2026)
Acadia Pharmaceuticals' quarterly Asset Utilization Ratio came in at 0.69 in Q1 2026, down 19.53% year-on-year from 0.86 in Q1 2025, and down 6.64% quarter-over-quarter from 0.74 in Q4 2025.
Acadia Pharmaceuticals has reported Asset Utilization Ratio for 16 years, with the latest figure at 0.69 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio fell 19.53% year-over-year to 0.69; the trailing twelve-month figure through Mar 2026 stood at 0.69 (down 19.53% YoY), and the FY2025 full-year result was 0.78, down 21.27% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.69, down from 0.74 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 1.05 in Q4 2023, with the low at 0.69 in Q1 2026.
- Average Asset Utilization Ratio over 5 years is 0.88, with a median of 0.86 recorded in 2025.
- Year-over-year, Asset Utilization Ratio surged 32.27% in 2022 and fell 19.53% in 2026.
- Tracing ACAD's Asset Utilization Ratio over 5 years: stood at 0.87 in 2022, then increased by 21.01% to 1.05 in 2023, then decreased by 15.85% to 0.88 in 2024, then dropped by 16.35% to 0.74 in 2025, then decreased by 6.64% to 0.69 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.69 (Q1 2026), 0.74 (Q4 2025), and 0.82 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.85 |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | 0.69 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.69 |
| Dec 31, 2025 | 0.74 |
| Sep 30, 2025 | 0.82 |
| Jun 30, 2025 | 0.86 |
| Mar 31, 2025 | 0.86 |
| Dec 31, 2024 | 0.88 |
| Sep 30, 2024 | 0.98 |
| Jun 30, 2024 | 1.01 |
| Mar 31, 2024 | 1.01 |
| Dec 31, 2023 | 1.05 |
| Sep 30, 2023 | 0.99 |
| Jun 30, 2023 | 0.85 |
| Mar 31, 2023 | 0.84 |
| Dec 31, 2022 | 0.87 |
| Sep 30, 2022 | 0.84 |
| Jun 30, 2022 | 0.83 |
| Mar 31, 2022 | 0.74 |
| Dec 31, 2021 | 0.68 |
| Sep 30, 2021 | 0.66 |
| Jun 30, 2021 | 0.63 |
| Mar 31, 2021 | 0.60 |
| Dec 31, 2020 | 0.56 |
| Sep 30, 2020 | 0.54 |
| Jun 30, 2020 | 0.52 |
| Mar 31, 2020 | 0.48 |
| Dec 31, 2019 | 0.44 |
| Sep 30, 2019 | 0.49 |
| Jun 30, 2019 | 0.55 |
| Mar 31, 2019 | 0.46 |
| Dec 31, 2018 | 0.55 |
| Sep 30, 2018 | 0.71 |
| Jun 30, 2018 | 0.56 |
| Mar 31, 2018 | 0.43 |
| Dec 31, 2017 | 0.31 |
| Sep 30, 2017 | 0.21 |
| Jun 30, 2017 | 0.13 |
| Mar 31, 2017 | 0.06 |
| Dec 31, 2016 | 0.03 |
| Sep 30, 2016 | 0.01 |
| Jun 30, 2016 | 0.00 |
| Mar 31, 2016 | 0.00 |
| Dec 31, 2015 | 0.00 |
| Sep 30, 2015 | 0.00 |
| Jun 30, 2015 | 0.00 |
| Mar 31, 2015 | 0.00 |
| Dec 31, 2014 | 0.00 |
| Sep 30, 2014 | 0.00 |
| Jun 30, 2014 | 0.00 |
| Mar 31, 2014 | 0.00 |
| Dec 31, 2013 | 0.01 |
| Sep 30, 2013 | 0.01 |
| Jun 30, 2013 | 0.03 |
| Mar 31, 2013 | 0.05 |
| Dec 31, 2012 | 0.07 |
| Sep 30, 2012 | 0.22 |
| Jun 30, 2012 | 0.09 |
| Mar 31, 2012 | 0.07 |
| Dec 31, 2011 | 0.06 |
| Sep 30, 2011 | 0.92 |